Notice: This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends VLON vs. LEXX, CLNN, ACST, PMN, LTRN, IRD, HOOK, OCUP, CTXR, and ALTSShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Lexaria Bioscience (LEXX), Clene (CLNN), Acasti Pharma (ACST), ProMIS Neurosciences (PMN), Lantern Pharma (LTRN), Opus Genetics (IRD), Hookipa Pharma (HOOK), Ocuphire Pharma (OCUP), Citius Pharmaceuticals (CTXR), and Janone (ALTS). These companies are all part of the "pharmaceutical preparations" industry. Vallon Pharmaceuticals vs. Lexaria Bioscience Clene Acasti Pharma ProMIS Neurosciences Lantern Pharma Opus Genetics Hookipa Pharma Ocuphire Pharma Citius Pharmaceuticals Janone Lexaria Bioscience (NASDAQ:LEXX) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking. Which has more risk and volatility, LEXX or VLON? Lexaria Bioscience has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Vallon Pharmaceuticals has a beta of -1.14, indicating that its stock price is 214% less volatile than the S&P 500. Does the MarketBeat Community favor LEXX or VLON? Lexaria Bioscience received 3 more outperform votes than Vallon Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformLexaria BioscienceOutperform Votes4100.00% Underperform VotesNo VotesVallon PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of LEXX or VLON? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 8.7% of Vallon Pharmaceuticals shares are owned by institutional investors. 7.6% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 37.3% of Vallon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is LEXX or VLON more profitable? Lexaria Bioscience's return on equity of -88.39% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lexaria BioscienceN/A -88.39% -84.05% Vallon Pharmaceuticals N/A -230.48%-124.89% Do analysts rate LEXX or VLON? Lexaria Bioscience presently has a consensus target price of $11.00, indicating a potential upside of 411.63%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Lexaria Bioscience is more favorable than Vallon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Vallon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor LEXX or VLON? In the previous week, Lexaria Bioscience's average media sentiment score of 0.31 beat Vallon Pharmaceuticals' score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the media. Company Overall Sentiment Lexaria Bioscience Neutral Vallon Pharmaceuticals Neutral Which has preferable earnings & valuation, LEXX or VLON? Lexaria Bioscience has higher revenue and earnings than Vallon Pharmaceuticals. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Vallon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$230K147.88-$6.66M-$0.44-4.89Vallon Pharmaceuticals$100K86.15-$7.02M-$0.78-0.82 SummaryLexaria Bioscience beats Vallon Pharmaceuticals on 13 of the 15 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.62M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.824.9791.2813.60Price / Sales86.15371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book3.5510.306.906.33Net Income-$7.02M$153.61M$118.83M$225.93M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$0.64-7.3%N/A-36.9%$8.62M$100,000.00-0.823Gap UpLEXXLexaria Bioscience1.867 of 5 stars$2.15-2.3%$11.00+411.6%+78.9%$34.01M$230,000.000.007News CoverageGap DownCLNNClene3.1607 of 5 stars$3.95-3.4%$71.33+1,705.9%-56.6%$33.02M$650,000.000.00100Analyst RevisionACSTAcasti Pharma2.3584 of 5 stars$3.37-0.9%$10.00+196.7%+59.0%$31.68MN/A-2.3432PMNProMIS Neurosciences1.1238 of 5 stars$0.96-3.5%N/A-30.8%$31.45M$10,000.000.006LTRNLantern Pharma1.0942 of 5 stars$2.88-2.0%N/A-27.0%$31.05MN/A0.0020Positive NewsIRDOpus Genetics3.0205 of 5 stars$0.98flat$8.00+716.3%N/A$30.94M$19.05M0.00N/ANews CoverageHOOKHookipa Pharma2.4671 of 5 stars$2.52-7.4%$38.33+1,421.2%-46.4%$30.39M$20.13M-0.6856Analyst ForecastGap DownOCUPOcuphire Pharma0.922 of 5 starsN/A$16.00+∞N/A$30.33M$16.45M-2.3914High Trading VolumeCTXRCitius Pharmaceuticals3.1588 of 5 stars$0.17-1.4%$4.00+2,286.6%-77.9%$30.29MN/A-0.7120Short Interest ↓ALTSJanone1.2188 of 5 stars$2.15-1.8%N/AN/A$30.25M$39.61M0.00170 Related Companies and Tools Related Companies LEXX Alternatives CLNN Alternatives ACST Alternatives PMN Alternatives LTRN Alternatives IRD Alternatives HOOK Alternatives OCUP Alternatives CTXR Alternatives ALTS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VLON) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
